Power Analytics Global's De-SPAC: What Investors Need to Know
Power Analytics Global is a mission-critical infrastructure software company going public through a merger with Drugs Made In America Acquisition Corp. (DMAA). The setup has upside if contract milestones support the valuation, but shareholders should watch redemption risk, dilution, and whether financing is actually locked in.
Power Analytics Global is a mission-critical infrastructure software company going public through a merger with Drugs Made In America Acquisition Corp. (DMAA). The setup has upside if contract milestones support the valuation, but shareholders should watch redemption risk, dilution, and whether financing is actually locked in.
Deal at a Glance
SPAC partner: Drugs Made In America Acquisition Corp.
SPAC ticker (trades now): DMAA
Implied valuation: $300M-$1.0B EV
Expected close: late Q3 to Q4 2026
Est. first trading date: late Q3 to Q4 2026
Deal status: Announced
Source filing: SEC 425 (2026-07-20)
Company Overview
Power Analytics Global describes itself as a global technology IoT, data, visualization, and analytics platform company focused on next-generation energy design, asset optimization, and predictive analytics. Its website says the platform combines software, cloud, and next-generation AI built on proprietary IP to protect mission-critical communications, data, and business operations.
The company says its products are used in data and network operations centers, manufacturing plants, nuclear facilities, deep sea oil platforms, aircraft carriers, submarines, FAA networks, and other complex infrastructure. It highlights products such as PowerPulse and Power Control Router, and says the total value of assets protected by its technology is more than $120 billion. The company says it was founded 25 years ago and is headquartered in Hoboken, New Jersey.
Industry-wise, PAGC is being positioned at the intersection of AI, advanced analytics, quantum-resistant security, and infrastructure digitization. The filings do not provide a formal TAM or competitor list, so the market framing is qualitative rather than fully quantified.
The SPAC Deal
Power Analytics Global is merging with Drugs Made In America Acquisition Corp. (current ticker: DMAA) in a milestone-based de-SPAC. The definitive merger agreement ties PAGC’s enterprise valuation to verified, signed, enforceable revenue contracts: $15 million to $25 million supports a $300 million enterprise valuation, $25 million to $50 million supports up to $500 million, $50 million to $75 million supports up to $750 million, and $75 million or more supports a $1.0 billion target valuation. The April 7 LOI said the valuation was anticipated to be about $1.0 billion, and the agreement also includes a $300 million floor valuation.
Trust cash and redemptions matter here. DMAA’s trust held $231.15 million at IPO, but the April 27, 2026 extension vote saw 9,440,230 ordinary shares redeemed and $99,336,017 removed from trust, leaving 24,276,913 ordinary shares outstanding after redemption. The filings also say the sponsor can fund monthly extensions by depositing the lesser of $300,000 or $0.04 per non-redeemed public share per month. The deal has not disclosed a signed PIPE, committed PIPE size, or investor list; additional financing is only described as something the parties may pursue. The post-merger dilution stack is meaningful because the filings say fully diluted shares will include founder shares, private placement shares, representative shares, 200,000 shares issued on March 11, 2025, 425,000 executive shares previously approved by the board, rights conversions, and any convertible notes or working capital loans outstanding at closing.
Status is announced and definitive, but not closed. Key dates disclosed are April 7, 2026 for the LOI, April 29, 2026 for the definitive merger agreement, July 14, 2026 for an amendment requiring DMAA to file the S-4 within 45 days after receipt of audited PAGC financials, and September 8, 2026 for an amended and restated definitive merger agreement. The filings reviewed do not include a shareholder vote date, effective S-4, or closing announcement. The expected post-merger ticker has not been disclosed, so the combined company’s trading symbol is still unknown. Based on the filing timeline, the first trading window looks like late Q3 to Q4 2026 if the deal clears the remaining steps.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The filings frame the SPAC route as a way to bring PAGC public while using a valuation structure tied to signed revenue contracts rather than a standard IPO pricing process. That matters because the company appears to be earlier in commercialization than a mature public software platform, and the merger agreement explicitly uses contract milestones to determine valuation.
A de-SPAC can also give the company a faster path to public capital markets and a sponsor-backed transaction structure. The tradeoff is that the company must still clear redemptions, financing, and closing conditions, and the final public float can be much smaller than the headline trust value if a large number of shareholders cash out.
Financial Highlights
The SEC materials reviewed do not disclose PAGC’s audited revenue, growth rate, gross margin, or backlog. The company website says it has thousands of customers and more than $120 billion of assets protected by its technology, but those are marketing claims rather than audited operating metrics. The merger agreement’s milestone-based valuation framework suggests the business is still being underwritten on contract traction rather than on a mature public-company financial profile.
Cash balance, losses, and runway are also not disclosed in the reviewed filings. Forward projections were not included in the materials I found, so there is no public bridge yet from current operating performance to the valuation tiers. Investors should watch for the S-4/proxy, where audited financials and any projections are expected to appear if disclosed.
Risk Factors
The biggest de-SPAC risk is redemptions. DMAA already experienced a large redemption event at the extension vote, removing $99.3 million from trust, and more redemptions at the merger vote could shrink the cash delivered to the combined company. That matters because the merger agreement contemplates a minimum cash condition of $25 million to $50 million, subject to redemptions and final negotiation.
Dilution is another major overhang. The filings point to founder shares, private placement shares, representative shares, rights conversions, and possible convertible notes or working capital loans at closing, all before any PIPE. The deal also has a floor valuation of $300 million, so if PAGC’s contract milestones or closing conditions slip below that level, DMAA can renegotiate or terminate. Other closing conditions include a debt-free condition, an IP schedule, and an active GSA CAGE code. The deal also has no disclosed PIPE, so financing uncertainty remains a live risk.
Comparable Public Companies
The filings do not disclose a formal peer set, so any comp list is an analytical approximation based on PAGC’s software, analytics, cybersecurity, and critical-infrastructure positioning. Public names that investors may compare against include Palantir (PLTR), CrowdStrike (CRWD), Snowflake (SNOW), and Oracle (ORCL), though each has a different business mix and scale.
As a group, those comps generally trade at premium software multiples relative to legacy enterprise tech, with the market rewarding recurring revenue, AI exposure, and mission-critical workflows. The key difference is that PAGC’s filings do not yet show the audited revenue base or recurring metrics that would normally support a clean public-company multiple comparison, so the valuation debate is still mostly about contract milestones and execution rather than current reported scale.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
The setup is interesting because the deal is not being sold as a generic SPAC story; it is being underwritten around verified contract milestones, with valuation stepping from $300 million to $1.0 billion as signed revenue contracts increase. That gives shareholders a concrete framework to watch, but it also means the market will care a lot about what the S-4 shows on audited financials, contract quality, and closing cash.
What shareholders should watch now is simple: redemptions, whether a PIPE or other financing gets locked in, and whether the company can clear the minimum cash and closing conditions without forcing a reset. The reason this matters now is that the transaction is still pending, the post-merger ticker has not been disclosed, and the first trading window likely sits in late Q3 to Q4 2026 if the process stays on track.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
